A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Bristol-Myers Squibb
Neonc Technologies, Inc.
M.D. Anderson Cancer Center
7 Hills Pharma, LLC
Vyriad, Inc.
University of Michigan Rogel Cancer Center
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC